Identification, prevention and management of cardiovascular risk in chronic myeloid leukaemia patients candidate to ponatinib: an expert opinion

M. Breccia, P Pregno, P. Spallarossa, Eleonora Arboscello, F. Ciceri, M. Giorgi, A. Grossi, M. Mallardo, Savina Nodari, S. Ottolini, C. Sala, G. Tortorella, G. Rosti, F. Pane, Giorgio Minotti, M. Baccarani

Research output: Contribution to journalArticle

Abstract

Ponatinib (Iclusig, ARIAD Pharmaceuticals-Incyte Co.) is a third-generation structure-guided tyrosine kinase inhibitor that is approved for treatment of Philadelphia chromosome-positive leukaemias resistant or intolerant to other inhibitors. The clinical use of ponatinib is complicated by the possible development of cardiovascular events, primarily hypertension and arterial or venous thrombotic events. The US Food and Drug Administration and the European Medicine Agency recommend that the cardiovascular profile of patients candidate for ponatinib should be carefully evaluated. For patients deemed to carry a high risk of cardiovascular events, other life-saving therapeutic options should be considered. When alternative options are not available, treatment with ponatinib is indicated but requires that haematologists and cardiologists collaborate and identify modalities of surveillance and risk mitigation in the best interest of the patient. This article reports on the expert opinion provided by a panel of Italian haematologists, cardiologists and clinical pharmacologists. It summarises suggestions that may help to improve the therapeutic index of ponatinib, primarily in the settings of chronic-phase chronic myeloid leukaemia. © 2016, Springer-Verlag Berlin Heidelberg.
Original languageEnglish
JournalAnnals of Hematology
Early online dateSep 30 2016
DOIs
Publication statusPublished - 2016

Keywords

  • Assessment
  • Cardiovascular risk
  • Chronic myeloid leukaemia
  • Management
  • Ponatinib

Fingerprint Dive into the research topics of 'Identification, prevention and management of cardiovascular risk in chronic myeloid leukaemia patients candidate to ponatinib: an expert opinion'. Together they form a unique fingerprint.

  • Cite this

    Breccia, M., Pregno, P., Spallarossa, P., Arboscello, E., Ciceri, F., Giorgi, M., Grossi, A., Mallardo, M., Nodari, S., Ottolini, S., Sala, C., Tortorella, G., Rosti, G., Pane, F., Minotti, G., & Baccarani, M. (2016). Identification, prevention and management of cardiovascular risk in chronic myeloid leukaemia patients candidate to ponatinib: an expert opinion. Annals of Hematology. https://doi.org/10.1007/s00277-016-2820-x